Funder: Canadian Frailty Network (CFN) and conducted through the SPOR Evidence Alliance; based on prior work funded by the World Health Organization (WHO)
To examine the rates of IE, HCV infection, and/or HIV infection in adults exposed to controlled release hydromorphone compared to the same infections in adults exposed through prescription or unregulated use of any formulation of immediate release hydromorphone
To determine the characteristics of adult HCR users who experienced IE, HCV infection and/or HIV infection, including previous treatment or hospitalization for opioid-related harms
